## In the United States Patent and Trademark Office

Serial Number:	
Appn. Filed: July 7, 2003	• • • • • •
Applicant(s): DALLAS L CLOUATRE	Hydroxyctus Acid
Appn. Title: Treating Cachefia and Cyterne California	•
Examiner/GAU:	2 2 2
Mailed: July / 20	ONICA CA
At: SANTA MC	NICA CH
Information Disclosure Statement	
Assistant Commissioner for Patents	
Washington, District of Columbia 20231	
Sir:	
Attached is a completed Form PTO-1449 and copies of the pertinent parts of the references cited thereon. Following	are comments on
any non-English-language references pursuant to Rule 98:	
Applicant(s): Dellas T Cloua +	
Applicant(s):	
<u> </u>	
Enc.: PTO-1449 & References	
c/o: DALLAS L CLOUATRE	
1247 LINCOLN BLVD #112	
SANTA MONICA, CA 90401	
Telephone: 310/656-0474	
Certificate of Mailing	
Explan	per postage affixed
in an envelope addressed to: "Assistant Commissioner for Patents, Washington, DC 20231" on the date below.	F
Date: 200_3 July 7	
Uale. 200	<del></del>

## LIST OF PRIOR ART CITED BY APPLICANT

Sheet 2 of 3

Dallas L. Clouatre
TREATING CACHEXIA AND EXCESSIVE CATABOLISM WITH (-)-HYDROXYCITRIC
ACID
July 7, 2003

## OTHER U.S. PATENT DOCUMENTS

5,626,849	06/1997	Hastings, et al.	424	195.1	

## OTHER PRIOR ART

Anonymous. Dronabinol (Marinol/Roxane). WholeHealthMD. http://www.wholehealthmd.com/refshelf/drugs.

Barber MD, et al. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer. 2001;40(2):118-24.

Hackenschmidt J,et al. Stimulation of acetyl-CoA carboxylase by (-)-Hydroxycitrate. FEBS Lett. 1972 Oct 15;27(1):131-133.

Heymsfield SB, et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280:1596-1600; also Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. Physiol Behav. 2000 Oct 1;71(1-2):87-94.

Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002 Mar-Apr;52(2):72-91.

Laviano A, et al. Neurochemical mechanisms for cancer anorexia. Nutrition. 2002 Jan;18(1):100-5.

McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. Medical Hypotheses 1994;42:215-225.

Nandi J, et al. Central mechanisms involved with catabolism. Curr Opin Clin Nutr Metab Care. 2002 Jul;5(4):407-18.

Ohia SE, et al. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX). Mol Cell Biochem. 2002 Sep;238(1-2):89-103.

Roubenoff R. Catabolism of aging: is it an inflammatory process? Curr Opin Clin Nutr Metab Care. 2003 May;6(3):295-9.

Roubenoff R, et al. Role of cytokines and testosterone in regulating lean body mass and resting energy expenditure in HIV-infected men. Am J Physiol Endocrinol Metab. 2002 Jul;283(1):E138-45.

Sato T, et al. Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia. Clin Nutr. 2003 Apr;22(2):139-46.

Sullivan AC, Triscari J. Metabolic regulation as a control for lipid disorders. I. Influence of (–)-hydroxycitrrate on experimentally induced obesity in the rodent. American Journal of Clinical Nutrition 1977;30:767-776.

Sullivan, Ann C. and Joseph Triscari. Possible interrelationhip between metabolite flux and appetite. In D. Novin, W. Wyriwicka and G. Bray, eds., Hunger: Basic Mechanisms and Clinical Implications (New York: Raven Press, 1976) 115-125.

Sullivan AC, Gruen RK. Mechanisms of appetite modulation by drugs. Federation Proceedings 1985;44,1:139-144.

Triscari J, Sullivan AC. Comparative effects of (–)-hydroxycitrate and (+)-allo-hydroxycitrate on acetyl CoA carboxylase and fatty acid and cholesterol synthesis *in vivo*. Lipids April 1977;12(4): 357-363.

						Sheet 1	of	3				
FORM PTO-1449 (Substitute)  LIST OF PRIOR ART CITED BY APPLICANT			ATTY	. DOCKET NO.		SERIAL NO.						
			APPL CL	ICANT OUATRE		GROUP						
(Use several sheem if necessary)				FILIN Ju	g daje ly 7, 2003					GROUP		
U.S. PATENT DOCUMENTS												
'EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	cuss	SUBCLASS	FILING DATE IFAPPPOPRATE				
	AA	20030119913	06/2003	Ohia,	et al.	514	574					
	AB	20020187943	12/2002	Maje	ed, et al.	514	27					
	AC	6,476,071			atre, et al.	514	557					
	AD	6,221,901	04/2001	Shriv	astava, et al.	514	458					
	AE	5,914,326	06/1999	McCa	rty, et al.	514	188					
	AF	5,783,603	07/1998	Maje	ed, et al.	514	574					
	AG	5,656,314	08/1997	Moffe	tt, et al.	426	271					
	ΑН	3,993,668	11/1976	Guthr	ie, et al.	260	343.6					
	Al	3,919,254	11/1975	Guthr	ie, et al.	260	343.6					
	AJ	3,767,678	10/1973	Guthr	ie, et al.	260	343.6					
	АK	3,764,692	10/1973	Lowe	nstein	424	279					
POREIGN PATENT DOCUMENTS												
	AL	W0-02/078616	10/2002									
	AM	WO 02/14477	02/2002	Maje	ed, et al.							
	AN											
	A0											
	ДP											
		OTHER P	RIOR ART (Inclu	તેલાલુ Aud	or, Tide, Dase, Persinen	Priges Erc.)						
	AR -	SEE ATTA	CHED SHE	ETS								
	AS .											
	AT .											
EXAMINER DATE CONSIDERED												

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not cleation is in conformance with MPEP 609; Draw line through cleation if not in conformance and not considered. Include copy of this form with next commendation to applicant.